1. OC-0599 Factors associated with SBRT doses in oligometastatic disease: an EORTC/ESTRO OligoCare analysis. (May 2022) Authors: Guckenberger, M.; Alongi, F.; Ricardi, U.; Scorsetti, M.; Balermpas, P.; Livi, L.; Lievens, Y.; Braam, P.; Jereczek- Fossa, B.A.; Stellamans, K.; Ratosa, I.; Peulen, H.; Widder, J.; Ramella, S.; Verbeke, L.; Dirix, P.; Khanfir, K.; Zilli, T.; Hemmatazad, H.; Jeene, P. Journal: Radiotherapy and oncology Issue: Volume 170(2022)Supplement 1 Page Start: S523 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PD-0740 Real-world patient & treatment characteristics of oligometastatic disease: results of OligoCare. (August 2021) Authors: Guckenberger, M.; Ricardi, U.; Scorsetti, M.; Balermpas, P.; Lievens, Y.; Alongi, F.; Livi, L.; Braam, P.; Jereczek-Fossa, B.A.; Stellamans, K.; Verbeke, L.; Peulen, H.; Khanfir, K.; Ramella, S.; Zilli, T.; Geets, X.; Hemmatazad, H.; Ivaldi, G.B.; Ratosa, I.; Jeene, P. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S568 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗